Cambridge University Hospitals announces Nicola Ayton as Chief Executive
Cambridge University Hospitals NHS Foundation Trust (CUH) has appointed Nicola Ayton as Chief Executive, following a competitive recruitment process. She had been serving as interim Chief Executive since 1 January 2026.
Nuala McBride joins Salus Wellness
Nuala McBride is a degree-qualified nutritionist registered under the UK's Association for Nutrition.
Clement Mind presents at UKABIF 2026: Managing Challenging Behaviours after Acquired Brain Injury
Dr Alberto Bonilla Miralles, Clinical & Occupational Psychologist and Director at Clement Mind, delivered a specialist presentation at the UK Acquired Brain Injury Forum (UKABIF) on evidence-based approaches to understanding and managing challenging behaviours following an acquired brain injury.
12 gene therapies converge on retinitis pigmentosa and a $3.4bn market by 2033
This month Gene Scope Intelligence (www.genescope-intelligence.com), a dedicated gene therapy market intelligence platform releases a brand new commercial analysis and demand forecast for new gene therapies directed at Retinitis Pigmentosa (RP).
Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage
FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platformNIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS TrustLondon, UK, 06 May 2026: Calla Lily Clinical Care, a wo
FUJIFILM Biosciences and NextCell launch new commercial platform comprised of RUO Stromal Cells and Cell Culture Media
Collaboration results in platform to help researchers overcome challenges in MSC research
Bio-Rad expands range of TrailBlazer Kits for Antibody Conjugation to StarBright Dyes
Expanded Range Increases Access to Bio-Rad’s StarBright™ Dyes for Flow Cytometry and Western Blot Applications in Immunology Research
Beware the next generation of phishing attacks
If phishing scams are supposed to trick people, why do so many of them still feel clumsy?
For years, the answer was simple: Most scams were mass-produced.
Weight loss drugs boom drives pharma R&D returns, but industry could face ‘bubble’ effect
Top global pharma companies’ return on R&D increased for third consecutive year; Growth is almost entirely driven by GLP-1 drugs - used to treat obesity and diabetes - and accounts for 38% of projected sales;Obesity drugs have displaced oncology dr
Sable&Hawkes deliver new multi-million environment development project for Luton and Dunstable NHS
Client: Bedfordshire Hospitals NHS Foundation Trust Project: New Acute Services & Multi-Ward Block
Innovate Cambridge to recognise a new wave of companies at the Business Weekly Awards
Innovate Cambridge has announced a new award category for this year’s prestigious Business Weekly Awards, recognising a new generation of science and technology companies redefining what successful innovation looks like.
Daniel Zeichner MP welcomes Astrazeneca’s £300 million investment as boost for Cambridge
Daniel Zeichner, MP for Cambridge, has welcomed the announcement made by the Prime Minister, Sir Keir Starmer, during Prime Minister’s Questions today that AstraZeneca will invest £300 million into the UK’s life sciences sector.
Lab Thread introduces Unified Lab Software Platform to streamline biological research
Connects scientific teams, data and workflows within a single, fully integrated digital lab management system
CMR Surgical Submits 510(k) Application to U.S. FDA to Expand Versius Plus™ into Gynecology
Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology. This Submission Builds On Extensive Global Clinical Experience in Gynecology and Continues CMR’s U.S. Market Expansion
EpilepsyGTx appoints Professor Dimitri Kullmann as Chief Scientific Officer
Appointment of UCL Neurologist will accelerate the delivery of novel gene therapies for refractory epilepsy
It’s time to govern your team’s AI use
Do you know which AI tools your team is using at work… and what they’re putting into them?
Most senior leaders we speak to think they do. Until we dig a little deeper.
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers
New PTC Harmony Thermal Cycler Line Expands Access to Reliable, High-Performance PCR Across Academic and Biopharma Laboratories
From licensing to integration: is decision-making in life sciences moving upstream?
Recent cross-border licensing activity involving China-origin biopharmaceutical assets suggests a subtle but important shift in how global partnerships are being structured. While attention often focuses on total deal value, the more meaningful signal may lie in the underlying terms.
PlaqueTec closes $5 million financing
Oversubscribed round backed by existing shareholders Investment will support development of cardiovascular disease database to be used to inform patient stratification and therapeutic development programmesCambridge, UK, 27 April 2026:
AstraZeneca and Northern Ireland Forge New Strategic Partnership Aiming to Transform Healthcare and Boost Innovation
Belfast, UK, April 24, 2026 – AstraZeneca and Northern Ireland Department of Health, the Department for the Economy and the Health Innovation Research Alliance NI (HIRANI) today announced their intent to enter into a first-of-its-kind strategic Memorandum of Understanding (MOU), aimed at transforming healthcare delivery and improving health outcomes for the people of Northern Ireland.
Build your next big, bold and beautiful controlled environment facility with Cleanroom Solutions
Guardtech’s turnkey brand are redefining high-spec cleanroom construction by marrying operational excellence and environmental efficiency with new installation innovation and stunning aesthetics
Building buyer personas that genuinely resonate with scientist buyers
Learn how stronger buyer personas can sharpen Life Sciences marketing strategy and access a free, ready-to-use template.
When both sides have rules: What this means for UK–China life sciences collaboration
For UK life sciences businesses engaging with China, the operating environment has become more structured than many still assume. Not because the opportunity has diminished — it has not — but because the conditions for realising it now require a different level of preparation.